Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
Elanco Animal Health
ELAN
$11.2B
| $9.31M | ﹤0.01% |
411,485
-317,809
| -44% | -$6.92M |
|
1727
SL Green Realty
SLG
$4.08B
| $9.29M | ﹤0.01% |
202,555
+88,733
| +78% | +$4.38M |
|
1728
NOV
NOV
$7.36B
| $9.26M | ﹤0.01% |
592,616
-56,201
| -9% | -$834K |
|
1729
Perimeter Solutions
PRM
$5.53B
| $9.26M | ﹤0.01% |
336,270
+136,896
| +69% | +$3.46M |
|
1730
Edgewise Therapeutics
EWTX
$4.69B
| $9.25M | ﹤0.01% |
372,738
+138,088
| +59% | +$2.77M |
|
1731
CALL
American Express
AXP
$232B
| $9.25M | ﹤0.01% |
25,000
| – | – |
|
1732
Brookfield
BN
$111B
| $9.24M | ﹤0.01% |
201,273
+54,546
| +37% | +$2.49M |
|
|
BULL
1733
Webull Corp
BULL
$4.23B
| $9.22M | ﹤0.01% |
1,186,107
+748,642
| +171% | +$7.53M |
|
1734
Broadstone Net Lease
BNL
$4.35B
| $9.21M | ﹤0.01% |
530,489
+216,762
| +69% | +$3.9M |
|
1735
Burford Capital
BUR
$968M
| $9.21M | ﹤0.01% |
1,032,890
-129,536
| -11% | -$1.27M |
|
1736
PUT
Reddit
RDDT
$30.4B
| $9.19M | ﹤0.01% |
40,000
-100,000
| -71% | -$21M |
|
1737
Novanta
NOVT
$6.33B
| $9.19M | ﹤0.01% |
77,265
-12,660
| -14% | -$1.44M |
|
1738
Independence Realty Trust
IRT
$4.01B
| $9.17M | ﹤0.01% |
524,875
-36,439
| -6% | -$604K |
|
1739
Duolingo
DUOL
$6.74B
| $9.15M | ﹤0.01% |
52,160
+46
| +0.1% | +$10.8K |
|
1740
Timken Company
TKR
$9.1B
| $9.14M | ﹤0.01% |
108,650
+14,182
| +15% | +$1.13M |
|
1741
Gentex
GNTX
$4.99B
| $9.13M | ﹤0.01% |
392,297
+166,453
| +74% | +$4.01M |
|
1742
RenaissanceRe
RNR
$13.3B
| $9.13M | ﹤0.01% |
32,460
-13,074
| -29% | -$3.44M |
|
1743
FNB Corp
FNB
$6.88B
| $9.12M | ﹤0.01% |
533,133
-13,083
| -2% | -$214K |
|
1744
Uranium Energy
UEC
$5.54B
| $9.12M | ﹤0.01% |
780,466
+136,616
| +21% | +$1.79M |
|
1745
Construction Partners
ROAD
$6.73B
| $9.1M | ﹤0.01% |
83,806
+8,565
| +11% | +$964K |
|
1746
Laureate Education
LAUR
$5.15B
| $9.09M | ﹤0.01% |
270,082
+51,863
| +24% | +$1.6M |
|
1747
CALL
Hims & Hers Health
HIMS
$6.71B
| $9.09M | ﹤0.01% |
280,000
+30,000
| +12% | +$1.28M |
|
1748
Li Auto
LI
$12B
| $9.09M | ﹤0.01% |
536,718
+334,518
| +165% | +$6.63M |
|
1749
Synaptics
SYNA
$4.2B
| $9.05M | ﹤0.01% |
122,324
+4,947
| +4% | +$347K |
|
1750
Pacira BioSciences
PCRX
$924M
| $9.04M | ﹤0.01% |
349,442
-20,810
| -6% | -$495K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.